Genmab — April 2024
-
@kkjoel - Jeg er ret meget enig med dig.
-
Kesimptas vækst er imponerende henset til, at stoffet har været på markedet nogle år. Spændende om den tager markedsandele fra Ocrevus. Ellers vil den ramme loftet snart. Lidt om MS markedet https://www.fortunebusinessinsights.com/industry-reports/multiple-sclerosis-drugs-market-100386
-
Godmorgen
-
ok, i see. this is from today https://www.roche.com/investors/updates/inv-update-2024-04-24 and this from february https://assets.roche.com/f/176343/x/5a5b5d48d1/240201_ir_fy23_en.pdf
patients free of disease activity (NEDA-3) at year 6 in both continuous and switch groups
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind